Bit.bio Raises $50 M Series C Round To Scale Human Cell Programming Technology

The company plans to use the funding to accelerate product development and accessibility, scale global operations, expand into the toxicology market, strengthen manufacturing, and create new datasets for AI model training.

Przemek Obloj, CEO of bit.bio, commented: "By providing reliable human cells for research and safety testing, we’re helping to accelerate drug development and build a world class life sciences business in the UK. Our technology reduces reliance on animal testing while improving the relevance and accuracy of pre-clinical research. With fresh backing from M&G and our wider investor base, we can accelerate development, from in silico model training through our most established in vitro discovery models and towards safety testing."

Led by CEO Przemek Obloj, bit.bio develops cell programming technology that produces functional, human-relevant cells and models at industrial scale, accelerating research, drug discovery, and development while supporting the adoption of New Approach Methodologies (NAMs).

Read Also - Rosberg Ventures Closes $100M Fund III To Support Nico Rosberg’s Long-Term VC Vision

Its AI-powered discovery platform identifies unique transcription factor combinations to program specific cell types, and its patented opti-ox technology converts induced pluripotent stem cells (iPSCs) into these cells with exceptional purity, consistency and scalability.

“The investment of patient capital into a fast-growing private UK company, spun out from the University of Cambridge, marks a major vote of confidence in innovation and the future of drug development in the UK. bit.bio’s platform makes cell programming reliable, scalable and commercially ready in a rapidly evolving field. As a long-term investor, M&G is committed to backing the next generation of UK businesses and driving economic progress. With a growing global footprint, bit.bio is a UK success story poised for international growth.”

Lord David Prior concluded: “bit.bio’s technology is world class and the opportunity is now converting that advantage into sustained commercial performance. I look forward to supporting the team as it expands its customer reach and becomes a key partner for pharmaceutical, biotech and research organisations worldwide.”

bit.bio’s expanding ioCells portfolio now includes over 50 products, such as ioWild Type Cells, ioDisease Model Cells, ioCRISPR-Ready Cells, and ioTracker Cells.

About bit.bio

Founded in 2016 bit.bio is an award-winning human synthetic biology company dedicated to “coding cells” to develop novel therapies. By harnessing advanced cellular programming, they aim to transform medicine, accelerate drug discovery and create innovative cures, bridging science and patient care with cutting-edge biotechnology.